Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia
Open Access
- 1 March 2001
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 15 (3) , 385-390
- https://doi.org/10.1038/sj.leu.2402044
Abstract
The level of minimal residual disease (MRD) early in treatment of acute lymphoblastic leukemia (ALL) strongly predicts the risk of marrow relapse. As a variety of methods of varying complexity have been separately used for detecting and quantifying MRD, we compared the prognostic utility of three methods – measurement of blast percentage on day 14 of treatment, detection of monoclonality on day 14 or day 35, and measurement of MRD by PCR-based limiting dilution analysis on day 14 or day 35. The study group comprised 38 children aged 1–15 with Philadelphia-negative B-lineage ALL who were uniformly treated and followed until relapse or for a minimum of 5 years. We also studied some of the technical factors which influence the ability to detect MRD. Measurement of blast percentage on day 14 by an expert morphologist, detection of monoclonality on day 35, and PCR-based measurement of MRD levels on days 14 and 35 all showed significant ability to divide patients into prognostic groups. Measurement of blast percentage on day 14 by routine morphology or detection of monoclonality on day 14 were not useful. The quality of DNA samples varied greatly, as determined by amplifiability in the PCR. However, virtually all amplifiable leukemic targets in a sample were detectable which suggests that the level of detection achieved by limiting dilution analysis is essentially determined by the amount of DNA which it is practicable to study. We conclude that quantification of MRD at the end of induction provides the full range of prognostic information for marrow relapse but is complex; detection of monoclonality on day 35 is simple and has good positive predictive value; and quantification of MRD on day 14 merits further study. PCR-based methods for measurement of MRD levels should incorporate a correction for variation in DNA amplifiability.Keywords
This publication has 18 references indexed in Scilit:
- Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemiaBlood, 2000
- INVESTIGATION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA BY MOLECULAR ANALYSISBritish Journal of Haematology, 1999
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia.Journal of Clinical Oncology, 1998
- Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial TherapyNew England Journal of Medicine, 1998
- Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemiaThe Lancet, 1998
- The use of monoclonal gene rearrangement for detection of minimal residual disease in acute lymphoblastic leukemia of childhoodLeukemia, 1997
- Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of inductionThe Lancet, 1994
- Detection and quantitation of neoplastic cells in acute lymphoblastic leukaemia, by use of the polymerase chain reactionBritish Journal of Haematology, 1991